From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer
| Autor: | Sisto Perdonà, Carmela Pisano, Sandro Pignata, Alessandro Izzo, Daniela Russo, Marilena Di Napoli, Sabrina Chiara Cecere, Sergio Venanzio Setola, Daniela Califano, Rosa Tambaro, Florinda Feroce, Laura Attademo, Sabrina Rossetti, Anna Spina |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Durvalumab medicine.drug_class medicine.medical_treatment Immunology Monoclonal antibody 03 medical and health sciences 0302 clinical medicine Atezolizumab Internal medicine PD-L1 medicine Humans Immunology and Allergy Immune Checkpoint Inhibitors Clinical Trials as Topic Chemotherapy biology business.industry Immunotherapy Clinical trial 030104 developmental biology Urinary Bladder Neoplasms 030220 oncology & carcinogenesis biology.protein Nivolumab business |
| Zdroj: | Immunotherapy. 13:67-77 |
| ISSN: | 1750-7448 1750-743X |
| Popis: | Monoclonal antibodies targeting the checkpoint inhibitors (CPIs), programmed cell death protein-1 or programmed cell death ligand-1, are changing the landscape of urothelial carcinoma therapeutics. Overall, clinical studies in metastatic or advanced urothelial cancer showed that CPIs provided a slight improvement in survival and a relevant advantage in safety, compared with chemotherapy. After reviewing published and ongoing trials, the authors discuss expected answers to unmet needs, with a special attention to the research of biological markers for patients with urothelial cancer eligible for treatment with CPIs in this article. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|